BioLineRx Stock (NASDAQ:BLRX)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.20

52W Range

$0.19 - $1.64

50D Avg

$0.37

200D Avg

$0.63

Market Cap

$19.41M

Avg Vol (3M)

$992.01K

Beta

0.87

Div Yield

-

BLRX Company Profile


BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IL

Employees

79

IPO Date

Jul 27, 2011

Website

BLRX Performance


BLRX Financial Summary


Dec 23Dec 22Dec 21
Revenue$4.80M--
Operating Income$-42.99M$-29.16M$-24.78M
Net Income$-60.61M$-18.87M$-28.14M
EBITDA$-41.61M$-22.14M$-23.43M
Basic EPS$-0.94$-0.37$-0.64
Diluted EPS$-0.94$-0.37$-0.64

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 25, 24 | 10:58 AM
Q2 24Aug 15, 24 | 3:03 PM
Q1 24May 28, 24 | 5:56 PM

Peer Comparison


TickerCompany
LXRXLexicon Pharmaceuticals, Inc.
ARQTArcutis Biotherapeutics, Inc.
FBIOFortress Biotech, Inc.
MCRBSeres Therapeutics, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
IBRXImmunityBio, Inc.
ACHLAchilles Therapeutics plc
MREOMereo BioPharma Group plc
APTOAptose Biosciences Inc.
ARDXArdelyx, Inc.
MBIOMustang Bio, Inc.
LPTXLeap Therapeutics, Inc.
VRCAVerrica Pharmaceuticals Inc.
VRNAVerona Pharma plc
TERNTerns Pharmaceuticals, Inc.
CDTXCidara Therapeutics, Inc.